Autolus Therapeutics plc
NASDAQ:AUTLBiotechnology
+$0.01 today
- Market cap
- $282.13M
- Beta
- 2.01
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.09
Volume 2.56M
Average 1.60M
AUTL Total Current Liabilities
All obligations due within one year.
Autolus Therapeutics plcNASDAQ: AUTL
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 4.5% from a year ago
Total current liabilities stood at $63.6M at the end of Q1 FY2026, down 4.5% from a year earlier and down 13.4% from the prior quarter. Over 3 fiscal years it compounded at +16.6% a year.
Context
- Total current liabilities amounted to 12.1% of total assets at the end of Q1 FY2026, up 3.1 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -4.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 73.44M USD
- Year-over-year change
- +20.9%
- 4-year CAGR
- +26.6%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 73.44M | +20.9% |
| FY2024 | 2024-12-31 | 60.74M | +35.8% |
| FY2023 | 2023-12-31 | 44.74M | -3.5% |
| FY2022 | 2022-12-31 | 46.37M | +62.4% |
| FY2021 | 2021-12-31 | 28.55M | — |
Total Current Liabilities vs competitors
How AUTL compares with its peers on the latest reported figures
- AUTL's Mar 2026 total current liabilities of $63.6M is the 3rd highest of the 10 companies compared; the peer median is $28.33M.
- Its year-over-year change of -4.5% is the 2nd highest of 10, against a peer median of -17.3%.
- Total current liabilities amounts to 12.1% of total assets for AUTL, versus a peer median of 10.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $289.6M | -33.2% | +28.8% | 17.2% | |
| Mar 2026 | $134.5M | -17.3% | +32.3% | 46.5% | |
| Mar 2026 | $63.6M | -4.5% | +16.6% | 12.1% | |
| Mar 2026 | $36.95M | -10.5% | +10.1% | 10.5% | |
| Mar 2026 | $30.69M | +9.0% | -31.9% | 10.8% | |
| Mar 2026 | $28.33M | -5.6% | -15.4% | 7.2% | |
| Mar 2026 | $19.67M | -31.0% | -3.3% | 13.2% | |
| Mar 2026 | $13.57M | -6.5% | -12.1% | 4.2% | |
| Mar 2026 | $7.76M | -37.4% | -46.9% | 5.4% | |
| Mar 2026 | $5.65M | -88.2% | -42.6% | 28.2% | |
| Peer median (excluding AUTL) | $28.33M | -17.3% | -12.1% | 10.8% | |
Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 310.34M | 382.44M | 239.57M | 227.38M | 104.13M |
| Short-term Investments | 0 | 0 | 0 | 360.64M | 196.58M |
| Net Receivables | 68K | 28.98M | 1.05M | 48.24M | 75.79M |
| Inventory | 0 | 0 | 0 | 4.14M | 33.21M |
| Other Current Assets | 27.83M | 2.02M | 26.05M | 5.32M | 4.93M |
| Total Current Assets | 346.95M | 425.77M | 275.3M | 660.93M | 435.92M |
| Property, Plant & Equipment (Net) | 52.32M | 58.42M | 95.65M | 105.05M | 128.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 65K | 0 | 0 | 12.37M | 19.81M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 2.08M | 3.06M | 3.24M | 3.56M |
| Other Non-current Assets | 6.23M | 4.01M | 1.36M | 1.13M | 1.28M |
| Total Non-current Assets | 58.61M | 64.5M | 100.08M | 121.8M | 153.15M |
| Total Assets | 405.56M | 490.27M | 375.38M | 782.73M | 589.07M |
| Account Payables | 431K | 531K | 103K | 1.97M | 3.08M |
| Short-term Debt | 0 | 0 | 0 | 0 | 14.57M |
| Tax Payables | 0 | 0 | 0 | 3.59M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 160K | 10.57M | 15.29M | 23.66M | 55.79M |
| Total Current Liabilities | 28.55M | 46.37M | 44.74M | 60.74M | 73.44M |
| Long-term Debt | 47.02M | 0 | 0 | 0 | 270.2M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 128K | 126.02M | 171.26M | 245.03M | 477K |
| Total Non-current Liabilities | 63.69M | 145.23M | 219.17M | 294.66M | 337.5M |
| Total Liabilities | 92.24M | 191.6M | 263.91M | 355.4M | 410.94M |
| Common Stock | 4K | 8K | 8K | 12K | 12K |
| Retained Earnings | (521.34M) | (670.18M) | (878.56M) | (1.1B) | (1.39B) |
| Accumulated OCI | (8.45M) | (38.9M) | (28.99M) | (29.17M) | (5.36M) |
| Other Stockholders Equity | (1) | 118K | 118K | 118K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 313.32M | 298.67M | 111.47M | 427.33M | 178.13M |
| Total Debt | 68.01M | 24.26M | 52.97M | 52.63M | 351.59M |
| Net Debt | (242.32M) | (358.18M) | (186.6M) | (174.75M) | 247.45M |
Autolus Therapeutics plc
NASDAQ:AUTL
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.